查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1759875

核酸增幅检查(NAAT)的世界市场规模，趋势，预测(2025年～2033年)

Global Nucleic Acid Amplification Testing (NAAT) Market Size, Trends & Forecast 2025-2033
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

核酸扩增检测 (NAAT) 市场规模及预测

全球核酸扩增检测 (NAAT) 市场规模预计将从 2024 年的 86.6 亿美元增至 2033 年的 237.9 亿美元，2025 年至 2033 年的复合年增长率为 11.88%。对癌症、传染病和遗传疾病快速且准确诊断的需求日益增长，推动着市场的发展。 PCR 检测已被广泛应用，尤其是在新冠疫情期间，这加速了 NAAT 技术的部署。

核酸扩增检测 (NAAT) 市场的关键成长动力

向即时侦测 (POCT) 的转变

向即时检测 (POCT) 的转变正在彻底改变诊断环境，因为它可以在诊所、机场和偏远地区等分散的地点进行快速的现场检测。这一趋势的驱动力在于，人们需要更快、更准确地获得诊断结果，而无需承受中心实验室处理的延迟。像 Cepheid 这样的公司正在开发小巧易用的诊断系统。

例如，Cepheid 于 2024 年 9 月宣布了一款新的概念验证系统，该系统可快速检测包括呼吸道病毒在内的多种疾病，旨在简化初级保健和急诊环境中的分子诊断。

随着科技的发展，POCT 在医疗保健领域的应用预计将变得越来越重要，有助于遏制传染病的传播并改善病患照护。

迈向高通量系统和自动化

随着实验室寻求提高生产力、减少人为错误并扩大营运规模以满足高检测量，NAAT 对自动化和高通量技术的需求日益增长。透过整合样本製备、扩增和分析步骤，全自动系统可以优化工作流程，并提供快速的周转时间和可靠的结果。

为了进一步提高通量，各公司正大力投资开发能够同时处理多个样本的先进机器人设备和软体。

例如，汉密尔顿公司于 2023 年 2 月推出了 Microlab STAR 自动化液体处理系统。该系统旨在支援高通量工作流程，并提高分子诊断实验室样本处理的准确性和效率。

科技发展

由于技术进步，这些诊断设备的性能和可近性得到了显着提高，这是全球市场成长的主要因素。扩增技术的进步，包括环介导等温扩增 (LAMP) 和快速聚合酶炼式反应 (PCR)，显着提高了检测速度和效率，从而可以更快地做出诊断和治疗决策。

例如，Bio-Rad Laboratories 于 2023 年 8 月推出了 ddPCR（数位液滴 PCR）技术，显着提高了识别低丰度核酸的灵敏度和准确性，提升了分子诊断的潜力。该技术于 2024 年 7 月推出。

透过实现远端监控和即时数据共享，与远距医疗平台和数据分析等数位健康解决方案的整合将进一步增强这些检测的实用性并推动市场扩张。

核酸扩增检测 (NAAT) 市场的课题

设备和侦测成本高

核酸扩增检测 (NAAT) 广泛实施的一个主要障碍是其成本高昂，尤其是在中低收入地区。先进的核酸扩增检测 (NAAT) 技术需要昂贵的设备和符合严格品质要求的特定试剂。此外，这些系统通常需要高技能的人员和设备齐全的实验室才能运作。这些资金基础设施需求对于规模较小的医疗机构和资源有限的地区来说可能是个负担。因此，儘管 NAAT 具有很高的灵敏度和特异性，但在世界许多地方尚未普及。这些成本障碍不仅阻碍了快速诊断和治疗，还影响了某些检测的使用，导致医疗保健服务和结果的不公平。

本报告提供全球核酸增幅检查(NAAT)市场相关调查，成长推动因素与课题，各市场区隔的分析，主要企业的分析等资讯。

目录

第1章 简介

第2章 调查和调查手法

第3章 摘要整理

第4章 市场动态

  • 成长促进因素
  • 课题

第5章 核酸增幅检查(NAAT)市场

  • 过去的市场趋势
  • 市场预测

第6章 市场占有率分析

  • 类别
  • 各用途
  • 各最终用途
  • 各国

第7章 类型

  • 聚合酵素链锁反应(PCR)检验
  • 恆温核酸增幅技术(INAAT)检验
  • 连接[酉每]链反应(LCR)试验

第8章 用途

  • 传染病检查
  • 肿瘤学检验
  • 其他

第9章 最终用途

  • 中央研究所·索引研究所
  • 医院
  • 其他

第10章 国家

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 比利时
    • 荷兰
    • 土耳其
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 泰国
    • 马来西亚
    • 印尼
    • 澳洲
    • 纽西兰
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东·非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非

第11章 价值链分析

第12章 波特的五力分析

第13章 SWOT分析

第14章 价格基准分析

  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company
  • Danaher Corporation
  • Abbott Laboratories
  • Illumina, Inc.
  • Siemens Healthineers
  • bioMerieux SA
  • Novartis AG
  • Bio-Rad Laboratories, Inc.
  • Seegene Inc.

第15章 主要企业的分析

  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company
  • Danaher Corporation
  • Abbott Laboratories
  • Illumina, Inc.
  • Siemens Healthineers
  • bioMerieux SA
  • Novartis AG
  • Bio-Rad Laboratories, Inc.
  • Seegene Inc.
简介目录

Nucleic Acid Amplification Testing Market Size and Forecast

Nucleic Acid Amplification Testing Market is expected to reach US$ 23.79 billion by 2033 from US$ 8.66 billion in 2024, with a CAGR of 11.88% from 2025 to 2033. The growing need for quick and precise diagnostics in cancer, infectious illnesses, and genetic disorders is propelling the market. PCR-based tests have been widely used, particularly during the COVID-19 epidemic, which has accelerated the deployment of NAAT technology.

Nucleic Acid Amplification Testing Global Market Report by Type (Polymerase Chain Reaction (PCR) Tests, Isothermal Nucleic Acid Amplification Technology (INAAT) Tests, Ligase Chain Reaction (LCR) Tests), Application (Infectious Disease Testing, Oncology Testing, Others), End Use (Central & Reference Laboratories, Hospitals, Others), Countries and Company Analysis, 2025-2033.

Global Nucleic Acid Amplification Testing Industry Overview

The market is growing as a result of increased R&D expenditures for creating innovative biotechnology diagnostic methods and rising demand for sophisticated fast diagnostics. Additionally, the need for various nucleic acid amplification testing methods has been driven by the rising frequency of infectious illnesses worldwide and the requirement for highly effective testing options to effectively control disease outbreaks. The need for quick and precise diagnostic techniques, including nucleic acid amplification, to identify the SARS-CoV-2 virus has grown as a result of COVID-19. To satisfy the strong demand for quick and point-of-care testing, major market participants have created novel product offerings, such as tests based on isothermal nucleic acid amplification technology.

For example, Abbott Laboratories' Abbott ID NOW COVID-19 test, which can provide positive findings in five minutes and negative results in thirteen, was granted Emergency Use Authorization (EUA) in March 2020. It is anticipated that these pandemic-driven strategic efforts would accelerate market expansion in the near future.

New opportunities for market expansion are being created by emerging infectious illnesses like the monkeypox virus. The introduction and regulatory approval of nucleic acid amplification test items for certain illnesses is proof of this. For example, Quest Diagnostics was granted the Emergency Use Authorization (EUA) by the U.S. FDA in September 2022 for their Quest Monkeypox PCR test, which was introduced in July 2022. Likewise, Todos Medical Ltd. commercially introduced their Monkey Pox PCR-based diagnostic in the United States in August 2022. Therefore, it is anticipated that these new infections would accelerate market expansion.

Key Factors Driving the Nucleic Acid Amplification Testing Market Growth

Shift toward point-of-care testing

By facilitating quick, on-site testing at dispersed locations like clinics, airports, and distant places, the move toward point-of-care testing is revolutionizing the diagnostic environment. The need for faster, more precise findings without the delays of central lab processing is what is driving this trend. Businesses like as Cepheid are developing small, easy-to-use systems.

For example, Cepheid introduced a new proof of concept system in September 2024 that offers quick findings for a variety of diseases, including respiratory viruses, and aims to streamline molecular diagnostics in primary care and emergency situations.

The use of point-of-care NAAT in healthcare settings is expected to become increasingly important as technology develops, helping to reduce the spread of infectious illnesses and improve patient care.

Transition to high-throughput systems and automation

As labs look to increase productivity, reduce human error, and scale operations to meet high test numbers, there is a growing need for automation and high-throughput technologies in NAAT. By combining the procedures for sample preparation, amplification, and analysis, fully automated systems optimize workflows and provide quicker turnaround times and more reliable findings.

To further increase throughput, businesses are making large investments in creating sophisticated robotic equipment and software that can handle several samples at once.

For example, Hamilton unveiled the Microlab STAR automated liquid handling system in February 2023. This system is intended to support high-throughput workflows, enhancing the accuracy and efficiency of sample processing in molecular diagnostics labs.

Developments in technology

The performance and accessibility of these diagnostic instruments are greatly improved by technological improvements, which are a major factor in the worldwide market's growth. Faster diagnostic and treatment decisions are now possible thanks to advancements in amplification techniques including loop-mediated isothermal amplification (LAMP) and fast polymerase chain reaction (PCR), which have significantly increased test speed and efficiency.

As an illustration, Bio-Rad Laboratories introduced ddPCR (digital droplet PCR) technology in August 2023, which greatly increases sensitivity and precision in identifying low-abundance nucleic acids and advances the potential of molecular diagnostics. This technology was introduced in July 2024.

By enabling remote monitoring and real-time data sharing, this integration with digital health solutions-such as telehealth platforms and data analytics-further increases the usefulness of these tests and propels market expansion.

Challenges in the Nucleic Acid Amplification Testing Market

High Cost of Equipment and Tests

One major obstacle to wider implementation of nucleic acid amplification testing (NAAT) is its high cost, especially in low- and middle-income areas. Expensive equipment and specific reagents that must adhere to strict quality requirements are needed for advanced NAAT technologies. Furthermore, these systems frequently require highly skilled workers and a well-equipped laboratory setting to function. Smaller healthcare facilities and locations with limited resources may find these financial and infrastructure requirements onerous. Because of this, even though NAAT has a high sensitivity and specificity, it is still not widely available in many regions of the world. This expense barrier contributes to inequities in healthcare delivery and results by impeding prompt diagnosis and treatment in addition to affecting the use of certain tests.

Complex Regulatory Landscape

It takes a lot of effort and resources to navigate the regulatory environment for nucleic acid amplification testing (NAAT). Strict standards for clinical validation, quality assurance, and performance testing are enforced by regulatory agencies, such as the FDA in the United States and the EMA in Europe. To prove accuracy, sensitivity, specificity, and repeatability under many circumstances, developers must submit copious amounts of data. These procedures frequently entail drawn-out clinical studies and thorough paperwork, which postpones market entrance and raises development costs dramatically. These requirements can be especially taxing on startups and smaller businesses. Global commercialization is further hampered by disparate foreign regulatory regulations. Public health results may be impacted by this disjointed and drawn-out approval procedure, which can impede innovation and limit patients' access to state-of-the-art diagnostic tools.

Nucleic Acid Amplification Testing Market Overview by Regions

Regional differences in the NAAT market include North America's superior healthcare systems, Europe's emphasis on innovation and regulation, Asia-Pacific's explosive expansion, and emerging nations' access and infrastructure issues. The following provides a market overview by region:

United States Nucleic Acid Amplification Testing Market

The market for nucleic acid amplification testing in the US is a crucial part of the country's diagnostic environment, which is distinguished by its sophisticated healthcare system and strong R&D environment. The diagnosis of viral illnesses, genetic abnormalities, and some types of cancer depends on NAAT approaches, such as polymerase chain reaction and isothermal amplification techniques. The rising incidence of infectious and chronic illnesses, the increased need for quick and precise diagnostics, and large expenditures in biotechnology and diagnostics are some of the reasons driving the market. Additionally, the United States enjoys robust reimbursement laws and a favorable regulatory environment, which support the broad implementation of NAAT across a range of healthcare settings, including as hospitals, diagnostic labs, and point-of-care facilities. This all-encompassing strategy highlights America's dominance in the worldwide NAAT business.

United Kingdom Nucleic Acid Amplification Testing Market

The nucleic acid amplification testing (NAAT) market in the United Kingdom represents a sizeable portion of the larger European diagnostics business. Integrating NAAT for a range of uses, such as genetic screening and infectious illness detection, has been made possible in large part by the UK's sophisticated healthcare system, which is headed by the National Health Service (NHS). The COVID-19 pandemic significantly sped up the use of NAAT, demonstrating its effectiveness in quick and precise diagnosis. This change has led to further expenditures in molecular diagnostics, which has improved testing capacity and encouraged innovation. Additionally, the UK's dedication to biotechnology research and development guarantees that NAAT technologies will continue to advance. The UK continues to lead NAAT developments, striking a balance between innovation and regulatory supervision to uphold high diagnostic standards as the need for customized treatment and early illness identification increases.

India Nucleic Acid Amplification Testing Market

The market for nucleic acid amplification testing (NAAT) in India is developing quickly due to rising healthcare expenditures and the rising prevalence of infectious disorders. Particularly since the pandemic, the nation has seen a sharp increase in testing due to the broad use of technologies like PCR and isothermal amplification techniques. Particularly in underprivileged areas, government programs like the National Tuberculosis Elimination Program have made it easier to include quick molecular tests like Truenat and CBNAAT into standard diagnostic procedures. Enhancing early illness diagnosis and expanding access to healthcare are the goals of these initiatives. The industry is expected to continue growing despite obstacles including high costs and inadequate infrastructure, thanks to continuous improvements in diagnostic technology and an emphasis on increasing testing capacities nationwide.

United Arab Emirates Nucleic Acid Amplification Testing Market

The market for nucleic acid amplification testing (NAAT) in the United Arab Emirates (UAE) is expanding quickly due to improvements in molecular diagnostics and higher healthcare spending. The UAE's healthcare system relies heavily on NAAT technologies, such polymerase chain reaction (PCR) and isothermal amplification techniques, which make it easier to identify genetic and infectious illnesses. The introduction of these tools was further pushed by the COVID-19 pandemic, underscoring their significance in public health response and surveillance. The incorporation of NAAT into clinical practice has been strengthened by government programs and collaborations with foreign healthcare professionals. The UAE is a leader in the regional molecular diagnostics market because of its dedication to innovation and high-quality healthcare, even in the face of obstacles like exorbitant costs and the requirement for specialized training.

Recent Developments in Nucleic Acid Amplification Testing Industry

  • October 2024 - The first diagnostic test for mpox, a disease brought on by the monkeypox virus, was authorized by the World Health Organization (WHO). In light of the disease's recent recurrence, its approval is a critical step in strengthening international efforts to identify and treat it. The test's excellent accuracy and efficiency guarantee quicker diagnosis and more effective containment tactics during outbreaks.

Market Segmentations

Type

  • Polymerase Chain Reaction (PCR) Tests
  • Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
  • Ligase Chain Reaction (LCR) Tests

Application

  • Infectious Disease Testing
  • Oncology Testing
  • Others

End Use

  • Central & Reference Laboratories
  • Hospitals
  • Others

Regional Outlook

North America

  • United States
  • Canada

Europe

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Belgium
  • Netherlands
  • Turkey

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • New Zealand

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • Saudi Arabia
  • United Arab Emirates
  • South Africa

All the Key players have been covered

  • Overview
  • Key Persons
  • Recent Development
  • SWOT Analysis
  • Revenue Analysis

Company Analysis:

  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company
  • Danaher Corporation
  • Abbott Laboratories
  • Illumina, Inc.
  • Siemens Healthineers
  • bioMerieux SA
  • Novartis AG
  • Bio-Rad Laboratories, Inc.
  • Seegene Inc.

Table of Contents

1. Introduction

2. Research & Methodology

  • 2.1 Data Source
    • 2.1.1 Primary Sources
    • 2.1.2 Secondary Sources
  • 2.2 Research Approach
    • 2.2.1 Top-Down Approach
    • 2.2.2 Bottom-Up Approach
  • 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Nucleic Acid Amplification Testing Market

  • 5.1 Historical Market Trends
  • 5.2 Market Forecast

6. Market Share Analysis

  • 6.1 By Type
  • 6.2 By Application
  • 6.3 By End Use
  • 6.4 By Countries

7. Type

  • 7.1 Polymerase Chain Reaction (PCR) Tests
    • 7.1.1 Market Analysis
    • 7.1.2 Market Size & Forecast
  • 7.2 Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
    • 7.2.1 Market Analysis
    • 7.2.2 Market Size & Forecast
  • 7.3 Ligase Chain Reaction (LCR) Tests
    • 7.3.1 Market Analysis
    • 7.3.2 Market Size & Forecast

8. Application

  • 8.1 Infectious Disease Testing
    • 8.1.1 Market Analysis
    • 8.1.2 Market Size & Forecast
  • 8.2 Oncology Testing
    • 8.2.1 Market Analysis
    • 8.2.2 Market Size & Forecast
  • 8.3 Others
    • 8.3.1 Market Analysis
    • 8.3.2 Market Size & Forecast

9. End Use

  • 9.1 Central & Reference Laboratories
    • 9.1.1 Market Analysis
    • 9.1.2 Market Size & Forecast
  • 9.2 Hospitals
    • 9.2.1 Market Analysis
    • 9.2.2 Market Size & Forecast
  • 9.3 Others
    • 9.3.1 Market Analysis
    • 9.3.2 Market Size & Forecast

10. Countries

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Analysis
      • 10.1.1.2 Market Size & Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Analysis
      • 10.1.2.2 Market Size & Forecast
  • 10.2 Europe
    • 10.2.1 France
      • 10.2.1.1 Market Analysis
      • 10.2.1.2 Market Size & Forecast
    • 10.2.2 Germany
      • 10.2.2.1 Market Analysis
      • 10.2.2.2 Market Size & Forecast
    • 10.2.3 Italy
      • 10.2.3.1 Market Analysis
      • 10.2.3.2 Market Size & Forecast
    • 10.2.4 Spain
      • 10.2.4.1 Market Analysis
      • 10.2.4.2 Market Size & Forecast
    • 10.2.5 United Kingdom
      • 10.2.5.1 Market Analysis
      • 10.2.5.2 Market Size & Forecast
    • 10.2.6 Belgium
      • 10.2.6.1 Market Analysis
      • 10.2.6.2 Market Size & Forecast
    • 10.2.7 Netherlands
      • 10.2.7.1 Market Analysis
      • 10.2.7.2 Market Size & Forecast
    • 10.2.8 Turkey
      • 10.2.8.1 Market Analysis
      • 10.2.8.2 Market Size & Forecast
  • 10.3 Asia Pacific
    • 10.3.1 China
      • 10.3.1.1 Market Analysis
      • 10.3.1.2 Market Size & Forecast
    • 10.3.2 Japan
      • 10.3.2.1 Market Analysis
      • 10.3.2.2 Market Size & Forecast
    • 10.3.3 India
      • 10.3.3.1 Market Analysis
      • 10.3.3.2 Market Size & Forecast
    • 10.3.4 South Korea
      • 10.3.4.1 Market Analysis
      • 10.3.4.2 Market Size & Forecast
    • 10.3.5 Thailand
      • 10.3.5.1 Market Analysis
      • 10.3.5.2 Market Size & Forecast
    • 10.3.6 Malaysia
      • 10.3.6.1 Market Analysis
      • 10.3.6.2 Market Size & Forecast
    • 10.3.7 Indonesia
      • 10.3.7.1 Market Analysis
      • 10.3.7.2 Market Size & Forecast
    • 10.3.8 Australia
      • 10.3.8.1 Market Analysis
      • 10.3.8.2 Market Size & Forecast
    • 10.3.9 New Zealand
      • 10.3.9.1 Market Analysis
      • 10.3.9.2 Market Size & Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Analysis
      • 10.4.1.2 Market Size & Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Analysis
      • 10.4.2.2 Market Size & Forecast
    • 10.4.3 Argentina
      • 10.4.3.1 Market Analysis
      • 10.4.3.2 Market Size & Forecast
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
      • 10.5.1.1 Market Analysis
      • 10.5.1.2 Market Size & Forecast
    • 10.5.2 UAE
      • 10.5.2.1 Market Analysis
      • 10.5.2.2 Market Size & Forecast
    • 10.5.3 South Africa
      • 10.5.3.1 Market Analysis
      • 10.5.3.2 Market Size & Forecast

11. Value Chain Analysis

12. Porter's Five Forces Analysis

  • 12.1 Bargaining Power of Buyers
  • 12.2 Bargaining Power of Suppliers
  • 12.3 Degree of Competition
  • 12.4 Threat of New Entrants
  • 12.5 Threat of Substitutes

13. SWOT Analysis

  • 13.1 Strength
  • 13.2 Weakness
  • 13.3 Opportunity
  • 13.4 Threats

14. Pricing Benchmark Analysis

  • 14.1 F. Hoffmann-La Roche Ltd
  • 14.2 Becton, Dickinson and Company
  • 14.3 Danaher Corporation
  • 14.4 Abbott Laboratories
  • 14.5 Illumina, Inc.
  • 14.6 Siemens Healthineers
  • 14.7 bioMerieux SA
  • 14.8 Novartis AG
  • 14.9 Bio-Rad Laboratories, Inc.
  • 14.10 Seegene Inc.

15. Key Players Analysis

  • 15.1 F. Hoffmann-La Roche Ltd
    • 15.1.1 Overviews
    • 15.1.2 Key Person
    • 15.1.3 Recent Developments
    • 15.1.4 SWOT Analysis
    • 15.1.5 Revenue Analysis
  • 15.2 Becton, Dickinson and Company
    • 15.2.1 Overviews
    • 15.2.2 Key Person
    • 15.2.3 Recent Developments
    • 15.2.4 SWOT Analysis
    • 15.2.5 Revenue Analysis
  • 15.3 Danaher Corporation
    • 15.3.1 Overviews
    • 15.3.2 Key Person
    • 15.3.3 Recent Developments
    • 15.3.4 SWOT Analysis
    • 15.3.5 Revenue Analysis
  • 15.4 Abbott Laboratories
    • 15.4.1 Overviews
    • 15.4.2 Key Person
    • 15.4.3 Recent Developments
    • 15.4.4 SWOT Analysis
    • 15.4.5 Revenue Analysis
  • 15.5 Illumina, Inc.
    • 15.5.1 Overviews
    • 15.5.2 Key Person
    • 15.5.3 Recent Developments
    • 15.5.4 SWOT Analysis
    • 15.5.5 Revenue Analysis
  • 15.6 Siemens Healthineers
    • 15.6.1 Overviews
    • 15.6.2 Key Person
    • 15.6.3 Recent Developments
    • 15.6.4 SWOT Analysis
    • 15.6.5 Revenue Analysis
  • 15.7 bioMerieux SA
    • 15.7.1 Overviews
    • 15.7.2 Key Person
    • 15.7.3 Recent Developments
    • 15.7.4 SWOT Analysis
    • 15.7.5 Revenue Analysis
  • 15.8 Novartis AG
    • 15.8.1 Overviews
    • 15.8.2 Key Person
    • 15.8.3 Recent Developments
    • 15.8.4 SWOT Analysis
    • 15.8.5 Revenue Analysis
  • 15.9 Bio-Rad Laboratories, Inc.
    • 15.9.1 Overviews
    • 15.9.2 Key Person
    • 15.9.3 Recent Developments
    • 15.9.4 SWOT Analysis
    • 15.9.5 Revenue Analysis
  • 15.10 Seegene Inc.
    • 15.10.1 Overviews
    • 15.10.2 Key Person
    • 15.10.3 Recent Developments
    • 15.10.4 SWOT Analysis
    • 15.10.5 Revenue Analysis